Abolaji S Olagunju
My name is Abolaji Samson Olagunju, a Ph.D. candidate at the Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Brazil.
Currently, my research focuses on the use of recombinant live attenuated vectors (bacteria) as a form of vaccine vectors for the induction of in vivo CD8+ T cells and to exert anti-tumor immune response in relation to different cell death mechanisms, for example, necroptosis and pyroptosis. At the moment, I am evaluating the effect of the deficiency of the regulatory and effector molecules of necroptosis (RIPK3 and MLKL) and pyroptosis (Caspase 1/11, gasdermin D) in the efficacy of recombinant LM. I look forward to gaining more insights in the areas of immuno-oncology, immunotherapy, and vaccines.
I am available for collaborations, and soon, I will be open for a postdoctoral position.
Abstracts this author is presenting:
